A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Latest Information Update: 15 Mar 2024
Price :
$35 *
At a glance
- Drugs Ipatasertib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IPATunity130
- Sponsors Chugai Pharmaceutical; Roche; Roche Farma
- 07 Dec 2023 Results from NCT03800836, NCT03337724 and NCT04177108 ; evaluating a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab)paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer published in the Clinical Cancer Research
- 07 Feb 2023 Status changed from active, no longer recruiting to completed.
- 12 Jan 2023 Planned End Date changed from 22 Dec 2022 to 31 Jan 2023.